These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

478 related articles for article (PubMed ID: 31151230)

  • 1. Cytomegalovirus Infections after Hematopoietic Stem Cell Transplantation: Current Status and Future Immunotherapy.
    Cho SY; Lee DG; Kim HJ
    Int J Mol Sci; 2019 May; 20(11):. PubMed ID: 31151230
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Treatment of CMV infection after allogeneic hematopoietic stem cell transplantation.
    Maffini E; Giaccone L; Festuccia M; Brunello L; Busca A; Bruno B
    Expert Rev Hematol; 2016 Jun; 9(6):585-96. PubMed ID: 27043241
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cytomegalovirus in hematopoietic stem cell transplant recipients - management of infection.
    Locatelli F; Bertaina A; Bertaina V; Merli P
    Expert Rev Hematol; 2016 Nov; 9(11):1093-1105. PubMed ID: 27690683
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The clinical impact of cytomegalovirus infection following allogeneic hematopoietic cell transplantation: Why the quest for meaningful prophylaxis still matters.
    Chan ST; Logan AC
    Blood Rev; 2017 May; 31(3):173-183. PubMed ID: 28173959
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cytomegalovirus in hematopoietic stem cell transplant recipients: Current status, known challenges, and future strategies.
    Boeckh M; Nichols WG; Papanicolaou G; Rubin R; Wingard JR; Zaia J
    Biol Blood Marrow Transplant; 2003 Sep; 9(9):543-58. PubMed ID: 14506657
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of Sirolimus Exposure on the Need for Preemptive Antiviral Therapy for Cytomeglovirus Infection after Allogeneic Hematopoietic Stem Cell Transplantation.
    Guglieri-Lopez B; Perez-Pitarch A; Garcia-Cadenas I; Gimenez E; Barba P; Rabella N; Hernandez-Boluda JC; Fox L; Valcarcel D; Esquirol A; Ferriols-Lisart R; Sierra J; Solano C; Navarro D; Martino R; Piñana JL
    Biol Blood Marrow Transplant; 2019 May; 25(5):1022-1030. PubMed ID: 30639821
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Therapeutic Vaccination of Hematopoietic Cell Transplantation Recipients Improves Protective CD8 T-Cell Immunotherapy of Cytomegalovirus Infection.
    Gergely KM; Podlech J; Becker S; Freitag K; Krauter S; Büscher N; Holtappels R; Plachter B; Reddehase MJ; Lemmermann NAW
    Front Immunol; 2021; 12():694588. PubMed ID: 34489940
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pre-transplant cytomegalovirus (CMV) serostatus remains the most important determinant of CMV reactivation after allogeneic hematopoietic stem cell transplantation in the era of surveillance and preemptive therapy.
    George B; Pati N; Gilroy N; Ratnamohan M; Huang G; Kerridge I; Hertzberg M; Gottlieb D; Bradstock K
    Transpl Infect Dis; 2010 Aug; 12(4):322-9. PubMed ID: 20487414
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cytomegalovirus Reactivation after Allogeneic Hematopoietic Stem Cell Transplantation is Associated with a Reduced Risk of Relapse in Patients with Acute Myeloid Leukemia Who Survived to Day 100 after Transplantation: The Japan Society for Hematopoietic Cell Transplantation Transplantation-related Complication Working Group.
    Takenaka K; Nishida T; Asano-Mori Y; Oshima K; Ohashi K; Mori T; Kanamori H; Miyamura K; Kato C; Kobayashi N; Uchida N; Nakamae H; Ichinohe T; Morishima Y; Suzuki R; Yamaguchi T; Fukuda T
    Biol Blood Marrow Transplant; 2015 Nov; 21(11):2008-16. PubMed ID: 26211985
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Cytomegalovirus infections following allogeneic hematopoietic stem cell transplantation: prophylaxis and treatment].
    Katayama Y; Iwato K
    Rinsho Ketsueki; 2019; 60(6):635-645. PubMed ID: 31281156
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The immune response to cytomegalovirus in allogeneic hematopoietic stem cell transplant recipients.
    Ciáurriz M; Zabalza A; Beloki L; Mansilla C; Pérez-Valderrama E; Lachén M; Bandrés E; Olavarría E; Ramírez N
    Cell Mol Life Sci; 2015 Nov; 72(21):4049-62. PubMed ID: 26174234
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Transfer of minimally manipulated CMV-specific T cells from stem cell or third-party donors to treat CMV infection after allo-HSCT.
    Neuenhahn M; Albrecht J; Odendahl M; Schlott F; Dössinger G; Schiemann M; Lakshmipathi S; Martin K; Bunjes D; Harsdorf S; Weissinger EM; Menzel H; Verbeek M; Uharek L; Kröger N; Wagner E; Kobbe G; Schroeder T; Schmitt M; Held G; Herr W; Germeroth L; Bonig H; Tonn T; Einsele H; Busch DH; Grigoleit GU
    Leukemia; 2017 Oct; 31(10):2161-2171. PubMed ID: 28090089
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Management of cytomegalovirus infection after hematopoietic stem cell transplantation].
    Nishida T
    Rinsho Ketsueki; 2020; 61(9):1417-1423. PubMed ID: 33162544
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Use of the cytomegalovirus pp65 antigenemia assay for preemptive therapy in allogeneic hematopoietic stem cell transplantation: a real-world review.
    Tan BH; Chlebicka NL; Low JG; Chong TY; Chan KP; Goh YT
    Transpl Infect Dis; 2008 Oct; 10(5):325-32. PubMed ID: 18627578
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Therapeutic strategies for cytomegalovirus in allogeneic hematopoietic cell transplantation.
    Nishihori T; Shaheen M; El-Asmar J; Aljurf M; Kharfan-Dabaja MA
    Immunotherapy; 2015; 7(10):1059-71. PubMed ID: 26507225
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A novel therapeutic cytomegalovirus DNA vaccine in allogeneic haemopoietic stem-cell transplantation: a randomised, double-blind, placebo-controlled, phase 2 trial.
    Kharfan-Dabaja MA; Boeckh M; Wilck MB; Langston AA; Chu AH; Wloch MK; Guterwill DF; Smith LR; Rolland AP; Kenney RT
    Lancet Infect Dis; 2012 Apr; 12(4):290-9. PubMed ID: 22237175
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Role of letermovir for prevention of cytomegalovirus infection after allogeneic haematopoietic stem cell transplantation.
    Razonable RR
    Curr Opin Infect Dis; 2018 Aug; 31(4):286-291. PubMed ID: 29746444
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antiviral Agents for Preventing Cytomegalovirus Disease in Recipients of Hematopoietic Cell Transplantation.
    Jaing TH; Wang YL; Chiu CC
    Viruses; 2024 Aug; 16(8):. PubMed ID: 39205242
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cytomegalovirus Infection in Solid Organ and Hematopoietic Cell Transplantation: State of the Evidence.
    Haidar G; Boeckh M; Singh N
    J Infect Dis; 2020 Mar; 221(Suppl 1):S23-S31. PubMed ID: 32134486
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Optimizing the treatment of cytomegalovirus infection in allo-HSCT recipients.
    Sun YQ; Ma R; Huang XJ
    Expert Rev Clin Immunol; 2023 Feb; 19(2):227-235. PubMed ID: 36541485
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 24.